Antiarrhythmic effect of ranolazine in combination with class iii drugs in an experimental whole-heart model of atrial fibrillation

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages e63-e71

  Frommeyer, Gerrit ^a   Milberg, Peter ^a   Uphaus, Timo ^a   Kaiser, Dennis ^a   Kaese, Sven ^a   Breithardt, Günter ^a   Eckardt, Lars ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Amiodarone; Atrial fibrillation; Atrial stretch; Dronedarone; Ranolazine

Indexed keywords

AMIODARONE; DRONEDARONE; RANOLAZINE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; EXPERIMENTAL RABBIT; FEMALE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ATRIUM PRESSURE; HEART LEFT ATRIUM; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; SINUS RHYTHM;

AMIODARONE; ATRIAL FIBRILLATION; ATRIAL STRETCH; DRONEDARONE; RANOLAZINE;

ACETANILIDES; ACTION POTENTIALS; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; PIPERAZINES; RABBITS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; SOTALOL;

EID: 84887982535     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12035     Document Type: Article

References (38)

1. Wasmer K, Eckardt L. Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 2011;13:1368-1374.
2. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J 2008;8:175-181.
3. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-1457.
4. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008;5:1019-1026.
5. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011;8:1281-1290.
6. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2011;108:673-676.
7. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009;20:796-802.
8. Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2330-2342.
9. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2010;3:88-95.
10. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56:1216-1224.
11. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation. Am J Cardiol 2012;110:673-677.
12. Frommeyer G, Kaiser D, Uphaus T, et al. Effect of ranolazine on ventricular repolarization in Class III anti-arrhythmic drug treated rabbits. Heart Rhythm 2012;9:2051-2058.
13. Milberg P, Frommeyer G, Ghezelbash S, et al. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace 2013;15:761-769.
14. Frommeyer G, Milberg P, Witte P, et al. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. Eur J Heart Fail 2011;13:1060-1069.
15. Candinas R, Frielingsdorf J, Ha HR, Carrel T, Turina M, Follath F. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Eur J Clin Pharmacol 1998;53:331-336.
16. Milberg P, Frommeyer G, Uphaus T, Kaiser D, Osada N, Breithardt G, Eckardt L. Electrophysiologic profile of dronedarone on the ventricular level: beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization. J Cardiovasc Pharmacol 2012;59:92-100.
17. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-225.
18. Zarse M, Stellbrink C, Athanatou E, Robert J, Schotten U, Hanrath P. Verapamil prevents stretch-induced shortening of atrial effective refractory period in langendorff-perfused rabbit heart. J Cardiovasc Electrophysiol 2001;12:85-92.
19. Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: antiarrhythmic and proarrhythmic effects. Circulation 1998;97:2567-2574.
20. Eijsbouts SC, Houben RP, Blaauw Y, Schotten U, Allessie MA. Synergistic action of atrial dilation and sodium channel blockade on conduction in rabbit atria. J Cardiovasc Electrophysiol 2004;15:1453-1461.
21. Kalifa J, Bernard M, Gout B, et al. Anti-arrhythmic effects of I (Na), I (Kr), and combined I (Kr)-I (CaL) blockade in an experimental model of acute stretch-related atrial fibrillation. Cardiovasc Drugs Ther 2007;21:47-53.
22. Zygmunt AC, Nesterenko VV, Rajamani S, Hu D, Barajas-Martinez H, Belardinelli L, Antzelevitch C. Mechanisms of atrial-selective block of Na channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol 2011;301:H1606-H1614.
23. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-910.
24. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009;53:1510-1516.
25. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42:20-29.
26. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:20r-28r.
27. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004;110:2453-2459.
28. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-2276.
29. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687.
30. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009;54:1089-1095.
31. Watanabe H, Watanabe I, Nakai T, et al. Frequency-dependent electrophysiological effects of flecainide, nifekalant and d, l-sotalol on the human atrium. Jpn Circ J 2001;65:1-6.
32. Kirchhof P, Engelen M, Franz MR, et al. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. Basic Res Cardiol 2005;100:112-121.
33. Milberg P, Tegelkamp R, Osada N, et al. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol 2007;18:658-664.
34. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997;96:1686-1695.
35. Ravelli F. Mechano-electric feedback and atrial fibrillation. Prog Biophys Mol Biol 2003;82:137-149.
36. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-671.
37. Kim D, Fu C. Activation of a nonselective cation channel by swelling in atrial cells. J Membr Biol 1993;135:27-37.
38. + channel in heart cells. Activation by arachidonic acid. J Gen Physiol 1992;100:1021-1040.